tislelizumab combined with chemotherapy for the perioperative treatment of esophageal squamous carcinoma

Conditions: Esophagus Cancer

Summary: evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy


Eligibility criteria:
inclusion criteria: * subjects were enrolled in the study and signed an informed consent form. * male or female patients between the ages of 18 and 75. * patients with esophageal squamous carcinoma diagnosed by histopathology. * according to the tnm staging system of esophageal cancer in the 8th edition of the ajcc,the disease is in the stage of ct3-4an0m0 or ct1b-4an+m0 (confirmed by thoracic and abdominal enhancement ct/mri), and the lesion is located in the thoracic segment. * ecog score: 0-1. * normal functioning of major organs, i.e. meeting the following criteria. 1. blood count (no blood transfusions, granulocyte colony-stimulating factor \[g-csf\], or other medications corrected within 14 days prior to treatment); and absolute neutrophil count (anc) ≥1.5×109/l; hemoglobin (hb) ≥9.0 g/dl; and platelet count (plt) ≥ 100 x 109/l; 2. blood biochemistry creatinine clearance ≥60 ml/min. total bilirubin (tbil) ≤ 1.5 x uln. albuminous aminotransferase (ast) or albuminous aminotransferase (alt) levels ≤ 2.5 x uln; * expected survival \> 6 months. * female subjects of childbearing potential and male subjects with partners of childbearing potential are required to use a medically approved contraceptive method during study treatment and for at least 6 months after the last treatment. exclusion criteria: * the presence of clinically uncontrolled chest that required repeated drainage or medical intervention (within 2 weeks prior to randomization) hydrocele, pericardial hydrocele or ascites; * known intolerance or resistance to chemotherapy specified in the trial protocol; * have received any other escc anti-tumor therapy (e.g., targeting pd-1, pd-l1, pd-l2) or other tumor immunotherapy, radiotherapy, targeted therapy, ablation, or other systemic or local anti-tumor therapy); * patients who have an active autoimmune disease or have a history of an autoimmune disease but may relapse may have a known abnormality history of body organ transplantation or allogeneic hematopoietic stem cell transplantation; * a history of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic disease, including pulmonary fibrosis, acute lung disease; * there were severe chronic or active patients requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment infection (including tuberculosis infection, etc.); * have a known history of hiv infection; * the presence of any serious or uncontrolled systemic disease, including but not limited to: unstable angina pectoris, congestive heart failure, new york heart association (nyha) grade ≥ 2 chronic heart failure; any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, cerebrovascular accident, or transient ischemic attack, during the 6 months prior to the first dose of the study; uncontrolled hypertension (i.e., ≥ ctc-ae level 2 hypertension after medication); active pulmonary tuberculosis; those who have a history of psychotropic substance abuse and cannot abstain or have mental disorders; * had other malignancies in the past 5 years (cured skin basal cell carcinoma, breast carcinoma in situ and except primary cervical cancer); * had received live vaccine within 28 days prior to enrollment; * have participated in other therapeutic clinical trials within 4 weeks; * and those deemed unsuitable for inclusion by the researchers.